Market Insight - German pharma positive it will ride out economic storm
This article was originally published in Scrip
Executive Summary
Hamstrung by health reforms, Germany's research-based pharmaceutical industry is crying out for less regulation so it can get back to the job of delivering innovation. A rethink of the policies designed to promote competition and fresh incentives for investment in biotech would also help push industry in the right direction. At the same time, German authorities need to take control of the country's finances, argues Faraz Kermani.